Powers ET, Kelly JW. From uncovering the mechanism of transthyretin aggregation to the drug tafamidis for ameliorating neurodegeneration and cardiomyopathy. In: Smith RA, Kaspar BK, Svendsen CN, editors. Neurotherapeutics in the Era of Translational Medicine. London: Academic Press; 2021:65–103.

Google Scholar 

Kelly JW. Does protein aggregation drive postmitotic tissue degeneration? Sci Transl Med. 2021;13:eaax0914. https://doi.org/10.1126/scitranslmed.aax0914.

Article  PubMed  PubMed Central  Google Scholar 

Jiang X, Smith CS, Petrassi HM, et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry. 2001;40:11442–52. https://doi.org/10.1021/bi011194d.

Article  PubMed  CAS  Google Scholar 

Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry. 1992;31:8654–60. https://doi.org/10.1021/bi00151a036.

Article  PubMed  CAS  Google Scholar 

Lai Z, Colón W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry. 1996;35:6470–82. https://doi.org/10.1021/bi952501g.

Article  PubMed  CAS  Google Scholar 

Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293:2459–62. https://doi.org/10.1126/science.1062245.

Article  PubMed  Google Scholar 

Hammarström P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 2003;299:713–6. https://doi.org/10.1126/science.1079589.

Article  PubMed  CAS  Google Scholar 

Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–66. https://doi.org/10.1016/j.jacc.2015.09.075.

Article  PubMed  CAS  Google Scholar 

Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97. https://doi.org/10.1016/S1474-4422(11)70246-0.

Article  PubMed  Google Scholar 

Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57:829–37. https://doi.org/10.1002/mus.26034.

Article  PubMed  PubMed Central  CAS  Google Scholar 

González-Moreno J, Dispenzieri A, Grogan M, et al. Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey. Cardiol Ther. 2024;13:117–35. https://doi.org/10.1007/s40119-023-00344-3.

Article  PubMed  Google Scholar 

Gentile L, Coelho T, Dispenzieri A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18:350. https://doi.org/10.1186/s13023-023-02962-5.

Article  PubMed  PubMed Central  Google Scholar 

Coelho T, Maurer MS, Suhr OB. THAOS - The transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76. https://doi.org/10.1185/03007995.2012.754348.

Article  PubMed  CAS  Google Scholar 

Chou CC, Vest R, Prado MA, et al. Proteostasis and lysosomal repair deficits in transdifferentiated neurons of Alzheimer’s disease. Nat Cell Biol. 2025;27:619–32. https://doi.org/10.1038/s41556-025-01623-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2872–91. https://doi.org/10.1016/j.jacc.2019.04.003.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. Heart Failure. 2019;7:709–16. https://doi.org/10.1016/j.jchf.2019.04.010.

Article  PubMed  Google Scholar 

Kleefeld F, Scherret E, Knebel F, et al. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis. Amyloid. 2022;29:92–101. https://doi.org/10.1080/13506129.2021.2014448.

Article  PubMed  CAS  Google Scholar 

Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68:161–72. https://doi.org/10.1016/j.jacc.2016.03.596.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Donnelly JP, Hanna M, Sperry BW, Seitz WH Jr. Carpal tunnel syndrome: a potential early, red-flag sign of amyloidosis. J Hand Surg Am. 2019;44:868–76. https://doi.org/10.1016/j.jhsa.2019.06.016.

Article  PubMed  Google Scholar 

Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014–20. https://doi.org/10.1016/j.jacc.2016.06.033.

Article  PubMed  Google Scholar 

Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140:16–26. https://doi.org/10.1161/circulationaha.118.038169.

Article  PubMed  CAS  Google Scholar 

Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS). Am Heart J. 2012;164:222-8.e1. https://doi.org/10.1016/j.ahj.2012.04.015.

Article  PubMed  CAS  Google Scholar 

Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the transthyretin amyloidosis outcomes survey (THAOS). J Card Fail. 2024;31:525–33. https://doi.org/10.1016/j.cardfail.2024.06.003.

Article  PubMed  Google Scholar 

Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol. 2010;20:54–62. https://doi.org/10.1016/j.sbi.2009.12.009.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519–26. https://doi.org/10.1161/circheartfailure.113.000890.

Article  PubMed  Google Scholar 

Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390:132–42. https://doi.org/10.1056/NEJMoa2305434.

Article  PubMed  CAS  Google Scholar 

Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67. https://doi.org/10.1001/jama.2013.283815.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nelson LT, Paxman RJ, Xu J, Webb B, Powers ET, Kelly JW. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid. 2021;28:24–9. https://doi.org/10.1080/13506129.2020.1808783.

Article  PubMed  CAS  Google Scholar 

Ioannou A, Fontana M, Gillmore JD. RNA targeting and gene editing strategies for transthyretin amyloidosis. BioDrugs. 2023;37:127–42. https://doi.org/10.1007/s40259-023-00577-7.

Article